NCT03090880.

Study name	Prophylaxis of venous thromboembolism in advanced lung cancer (PROVE)
Methods	Randomised, phase III, open, multicentre trial with blinded adjudication of endpoints
Participants	Adults aged > 18 years with stage IV non‐small‐cell lung cancer and elevated D‐dimer > 1500 µg/L
Interventions	Intervention: tinzaparin 4500 IU SC once daily for 6 months Control: usual care
Outcomes	Primary outcome: VTE including symptomatic or incidental PE, symptomatic or incidental proximal DVT of the lower extremity, symptomatic DVT of the upper extremity, VTE‐related death during the six‐month treatment period Secondary outcomes: symptomatic VTE, any VTE, major bleeding, death at 6 and 12 months
Starting date	March 2017
Contact information	Guy Meyer
Notes	ClinicalTrials.gov identifier: NCT03090880